The liver disease treatment market was valued at USD 22.23 Billion in 2025. It is poised to grow at a CAGR of 10.40% during the forecast period of 2026-2035, and reach USD 59.79 Billion by 2035. The market growth is driven by the rising prevalence of liver disorders, increasing alcohol consumption, and growing hepatitis cases, supported by advancements in therapeutics and diagnostics, improving treatment access and patient outcomes globally.
Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for liver disease treatment conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for liver disease treatment indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Other key players in the market are GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., Takeda Pharmaceutical Co., and Novartis AG.
Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the Liver Disease Treatment Market
United States: The Liver Disease Treatment Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for liver disease treatment conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for liver disease treatment indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Key Takeaways
Government
- Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential liver disease treatment treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
- Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
- Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing liver disease treatment treatment.
Market
- Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for liver disease treatment manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
- The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
- Healthcare system demand for liver disease treatment treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.
Procurement
- Pharmaceutical procurement teams should build 90-day safety stock for essential liver disease treatment treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
- API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
- Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive liver disease treatment therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.
Key Market Trends and Insights
- By treatment type, the antiviral drugs segment held the highest market share of above 39% in the historical period.
- By disease type, viral hepatitis accounted for a 42% share of the market size in the historical period.
- By country, the United States dominates the market, holding more than 40% of the market share in the historical period.
Market Size and Forecast
- Market Size (2025): USD 22.23 Billion
- Projected Market Size (2035): USD 59.79 Billion
- CAGR (2026-2035): 10.40%
Liver Disease Treatment Market Overview
The market is expanding due to the rising incidence of chronic liver conditions, including hepatitis and fatty liver disease. Advancements in therapeutics and diagnostics are improving patient outcomes. Increasing awareness and early diagnosis contribute to market growth. Liver disease management is becoming more comprehensive, supported by innovation in drug development and growing healthcare infrastructure across key global regions. The market reached a value of approximately USD 22.23 Billion in 2025.Liver Disease Treatment Market Growth Drivers
Increasing FDA Regulatory Milestones to Propel Product Innovation and Market Advancement
Surging obesity-linked liver disease rates and strong regulatory support are primary drivers propelling product innovation across the liver treatment sector. For instance, in August 2025, the FDA approved Novo Nordisk's Wegovy (semaglutide) for MASH, marking the first GLP-1 receptor agonist cleared for this indication. This milestone is expected to catalyze new pipeline investments and broaden therapeutic access throughout the forecast period, strengthening liver disease management.Liver Disease Treatment Market Trends
Key trends shaping the market include rising adoption of antivirals, increasing focus on early diagnosis, and advancements in targeted treatment approaches globally.Rising Drug Approvals and Research Driving the Market Expansion
The growing global prevalence of metabolic liver diseases and escalating pharmaceutical R&D investments are reshaping the treatment landscape. Novel nucleic acid therapeutics represent significant opportunities supporting market expansion. For instance, in January 2026, McMaster University and Espervita Therapeutics disclosed preclinical data showing EVT0185 reversed liver fibrosis and improved metabolic markers, reinforcing investor confidence in next-generation pipelines entering the forecast period, supporting liver therapeutics innovation.Liver Disease Treatment Market Segmentation
Market Breakup by Treatment Type
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
- Others
Market Breakup by Disease Type
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic fatty Liver Disease
- Cancer
- Genetic and Pediatric Disorders
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)/MASH
- Others
Market Breakup by Drug Class
- Small-molecule Orals
- Biologics and Monoclonal Antibodies
- Cell and Gene Therapy
- RNA-based Therapeutics
Market Breakup by Route of Administration
- Oral
- Injectable
Market Breakup by End User
- Hospitals and Clinics
- Diagnostic Centers
- Ambulatory Surgery Centers
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Liver Disease Treatment Market Share
Antiviral drugs Expected to Lead the Market Segment by Treatment Type
The antiviral drugs segment held the highest market share of above 39% in the historical period, driven by strong demand for hepatitis therapies and proven clinical effectiveness. Increasing diagnosis rates and treatment accessibility further supported segment dominance. The market growth remains influenced by innovation in antiviral drug development and expanding patient populations, is expected to sustain the segment’s leading position over the forecast period.Liver Disease Treatment Market Analysis by Region
The United States dominated the market, holding more than 40% of the market share historically, supported by advanced healthcare infrastructure and high treatment adoption rates. Strong reimbursement systems and early access to innovative therapies are expected to continue supporting regional growth. Furthermore, consistent investment in research and development, along with the rising prevalence of chronic liver conditions, is expected to sustain the country’s leading position in the liver disease treatment market over the forecast period.Leading Players in the Liver Disease Treatment Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbott Laboratories
Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott Laboratories is a global healthcare company with a strong diagnostics portfolio supporting liver disease detection. Its offerings include hepatitis and liver function testing solutions. Liver disease diagnostics play a key role in its portfolio, enabling early screening and monitoring.Astellas Pharma Inc.
Established in 2005 and headquartered in Tokyo, Astellas Pharma Inc. focuses on innovative therapies, including liver-related diseases. Its portfolio includes treatments targeting hepatology and fibrosis pathways. Hepatology therapeutics remain a strategic focus, supported by ongoing research into chronic liver conditions and metabolic disorders.Bristol-Myers Squibb Company
Founded in 1887 and based in New York, Bristol-Myers Squibb Company is a leading biopharmaceutical firm with a focus on oncology and immunology, including liver cancer treatments. Its portfolio includes therapies for hepatocellular carcinoma. Liver cancer treatment represent a key major segment within its oncology pipeline.Gilead Sciences
Founded in 1987 and headquartered in Foster City, California, Gilead Sciences is a leader in antiviral therapies, particularly hepatitis B and C treatments. Its portfolio has transformed liver disease care globally. Antiviral liver therapy remains central, with continued innovation in chronic viral hepatitis management.Other key players in the market are GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., Takeda Pharmaceutical Co., and Novartis AG.
Key Questions Answered in the Liver Disease Treatment Market Report
- What was the liver disease treatment market value in 2025?
- What is the liver disease treatment market forecast outlook for 2026-2035?
- What major factors aid the demand for liver disease treatment market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major liver disease treatment market trends?
- Which treatment type is expected to dominate the market segment?
- Which disease type is expected to dominate the market segment?
- Which drug class is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Who are the key players in the liver disease treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
More Insights On
Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast
Table of Contents
1 Preface
3 Liver Disease Treatment Market Overview: 8 Major Markets
4 Liver Disease Overview
5 Patient Profile
6 Liver Disease Epidemiology Scenario and Forecast - 8 Major Markets
7 Liver Disease Treatment Market Landscape: 8 Major Markets
8 Clinical Trials and Pipeline Analysis
9 Liver Disease Treatment Market Challenges and Unmet Needs
11 Liver Disease Treatment Market Dynamics
12 Liver Disease Treatment Market Segmentation: 8 Major Markets
13 United States Liver Disease Treatment Market (219-2035)
14 United Kingdom Liver Disease Treatment Market (219-2035)
15 Germany Liver Disease Treatment Market (219-2035)
16 France Liver Disease Treatment Market (219-2035)
17 Italy Liver Disease Treatment Market (219-2035)
18 Spain Liver Disease Treatment Market (219-2035)
19 Japan Liver Disease Treatment Market (219-2035)
20 India Liver Disease Treatment Market (219-2035)
21 Regulatory Framework
22 Patent Analysis
23 Funding and Investment Analysis
24 Strategic Initiatives
25 Supplier Landscape
Companies Mentioned
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Gilead Sciences
